Lercanidipine, Enalapril, and Their Combination in the Treatment of Elderly Hypertensive Patients
Several trials have shown that hypertensive patients whose blood pressure (BP) is brought under control (< 140/90 mmHg) have significantly fewer cardiovascular events than patients whose BP remains uncontrolled . However, despite the availability of multiple antihypertensive drugs, BP is difficult to control, especially systolic BP and in elderly patients . In most clinical trials aimed at controlling BP, more than two antihypertensive drugs are almost always required. The importance of combination therapy has been emphasized in current guidelines . Adding a second antihypertensive drug may be a better option in non-controlled patients than switching to a different drug or increasing the dose of the first compound.
KeywordsAmbulatory Blood Pressure Monitoring Office Blood Pressure Elderly Hypertensive Patient Dihydropyridine Calcium Antagonist Office Systolic Blood Pressure
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Benetos A, Thomas F, Bean KE, Guize L (2003) Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 21:1635–1640PubMedCrossRefGoogle Scholar
Mancia G, Grassi G (2002) Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20:1461–1464PubMedCrossRefGoogle Scholar
Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure. JAMA 289:2560–2572PubMedCrossRefGoogle Scholar
Borghi C (2005) Lercanidipine in hypertension. Vasc Health Risk Manag 1:173–182PubMedGoogle Scholar
Todd PA, Goa LG (1992) Enalapril: a reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 43:346–381PubMedCrossRefGoogle Scholar
Julius S, Kjeldsen E, Weber M et al (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031PubMedCrossRefGoogle Scholar
© Springer-Verlag Italia 2007